ReviewClinical and experimental gastroenterology2015
Optimal management of steroid-dependent ulcerative colitis.
Review in Clinical and experimental gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Protective effects and possible mechanisms of matrine-type alkaloids (matrine and oxymatrine) in animal models of ulcerative colitis: a preclinical systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.Journal of Crohn's & colitis · 2024Trial
- Trial
- Efficacy of Biologics in Patients with Ulcerative Colitis Exhibiting Non-Response or Insufficient Response to Cytapheresis.Journal of clinical medicine · 2025Article
- Garlic Peel-Derived Phytochemicals Using GC-MS: Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Effects in Ulcerative Colitis Rat Model.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Ionically bridged dexamethasone sodium phosphate-zinc-PLGA nanocomplex in alginate microgel for the local treatment of ulcerative colitis.Archives of pharmacal research · 2023Article
- Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy.World journal of gastroenterology · 2022Review
- Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis.World journal of gastroenterology · 2021Article
- RhoA and Cdc42 in T cells: Are they targetable for T cell-mediated inflammatory diseases?Precision clinical medicine · 2021Article
- Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.Inflammatory bowel diseases · 2020Article
- Article
- Review of the epidemiology and burden of ulcerative colitis in Latin America.Therapeutic advances in gastroenterology · 2020Review
- Ulcerative Colitis: Shifting Sands.Drugs in R&D · 2019Review
- Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis.Internal medicine (Tokyo, Japan) · 2017Article
- Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new?World journal of gastrointestinal surgery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory condition that is variable in both extent and severity of disease as well as response to therapy. Corticosteroids (CSs) were the first drugs used in the management of UC and are still used for induction of remission. However, because of their extensive side-effect profile, they are not utilized for maintenance of remission. In view of this, CS-free remission has become an important end point while evaluating therapeutic agents used in the management of UC. This review highlights the results of various studies conducted to evaluate the efficacy of different medications to attain CS-free remission in the setting of active UC. The drugs reviewed include established agents such as thiopurines, methotrexate, infliximab, adalimumab, vedolizumab, golimumab, and newer experimental agents, and if all else fails, colectomy will be performed. The efficacy of these drugs is evaluated individually. Our aim is to provide a synopsis of the work done in this field to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.